Franck Carbonnel
University of Paris-Sud
Ulcerative colitisDiabetes mellitusGeneral surgeryMedicineGastroenterology
What is this?
Publications 191
#1L. Cachen (University of Paris-Sud)
#2Gaetane Nocturne (University of Paris-Sud)H-Index: 18
Last. Raphaèle Seror (University of Paris-Sud)H-Index: 38
view all 7 authors...
Background: Axial spondyloarthritis (axSpA) is a chronic, inflammatory disease that primarily affects the axial skeleton. Secukinumab is a human monoclonal antibody that binds to the protein interleukin (IL)-17A. Although some studies showed that obesity had a negative effect on the efficacy of tumor necrosis factor alpha inhibitor (TNFα -i) treatment in AS patients (1), no data is available for secukinumab. Objectives: To evaluate the effect of obesity on the treatment response and drug surviva...
#1Robert Salameh (Paris 12 Val de Marne University)H-Index: 1
#2Julien Kirchgesner (University of Paris)H-Index: 10
Last. Aurelien Amiot (Paris 12 Val de Marne University)H-Index: 22
view all 8 authors...
BACKGROUND: The long-term outcome of patients with acute severe ulcerative colitis (ASUC) responding to intravenous steroids (IVS) has been poorly reported. AIMS: To assess relapse-free survival in patients with ASUC responding to IVS. METHODS: Between January 2006 and December 2017, 142 consecutive patients with ASUC (according to modified Truelove-and-Witts criteria) responding to IVS were included in this multicentre retrospective study. Relapse was defined by a partial Mayo Clinic score >4 a...
1 CitationsSource
OBJECTIVES: To estimate the systemic serious adverse event (SAE) rates after colonoscopy and to identify their risk factors. METHODS: A nationwide cohort study was conducted using the comprehensive French claims databases SNDS (National Health Data System). Patients aged 30 years and over who underwent a first screening or diagnostic colonoscopy in 2010-2015 were included. The rates of cardiovascular and renal SAEs were estimated within 5 days after colonoscopy. The standardized incidence ratios...
BACKGROUND: A clinical decision support tool (CDST) has been validated for predicting treatment effectiveness of vedolizumab (VDZ) in Crohn's disease. AIM: To assess the utility of this CDST for predicting exposure-efficacy and disease outcomes. METHODS: Using data from three independent datasets (GEMINI, GETAID and VICTORY), we assessed clinical remission rates and measured VDZ exposure, rapidity of onset of action, response to dose optimisation and progression to surgery by CDST-defined respon...
3 CitationsSource
#1Loriane Lair-Mehiri (Paris Diderot University)H-Index: 1
#2Carmen Stefanescu (Paris Diderot University)H-Index: 15
Last. Yoram Bouhnik (Paris Diderot University)H-Index: 59
view all 18 authors...
Abstract Background Phase III trials demonstrated effectiveness of tofacitinib, an oral Janus kinase inhibitor, to induce and maintain remission in patients with moderate-to-severe active ulcerative colitis (UC). Aims We report the real-world effectiveness and safety of tofacitinib in patients with UC in France. Methods From February 2017 to December 2018, we performed a national French cohort study, which included all consecutive patients with an active UC refractory to anti-TNF and vedolizumab...
6 CitationsSource
#1Harinakshi Sanikini (Imperial College London)H-Index: 2
#2David C. Muller (Imperial College London)H-Index: 20
Last. Amanda J. Cross (Imperial College London)H-Index: 52
view all 40 authors...
Obesity has been associated with upper gastrointestinal cancers; however, there are limited prospective data on associations by subtype/subsite. Obesity can impact hormonal factors, which have been hypothesized to play a role in these cancers. We investigated anthropometric and reproductive factors in relation to esophageal and gastric cancer by subtype and subsite for 476,160 participants from the European Prospective Investigation into Cancer and Nutrition cohort. Multivariable hazard ratios (...
1 CitationsSource
#1Antoine MartinH-Index: 40
#1Antoine MartinH-Index: 1
Last. Aurelien AmiotH-Index: 22
view all 42 authors...
INTRODUCTION: It is unclear whether vedolizumab therapy can be discontinued in patients with inflammatory bowel disease (IBD) after achieving steroid-free clinical remission. AIM: To assess the risk of relapse after vedolizumab therapy was discontinued. PATIENTS AND METHODS: Retrospective observational study, collecting data from 21 tertiary centres affiliated with the GETAID from January 2017 to April 2019. Consecutive patients with IBD who were in steroid-free clinical remission for at least t...
1 CitationsSource
#1Guillaume Le BautH-Index: 1
Last. Laurent Beaugerie (University of Paris)H-Index: 14
view all 34 authors...
Abstract: Background & Aims There is consensus on the criteria used to define acute severe ulcerative colitis (ASUC) and on patient management, but it has been a challenge to identify patients at risk for colectomy based on data collected at hospital admission. We aimed to develop a system to determine patients' risk of colectomy within 1 y of hospital admission for ASUC based on clinical, biomarker, and endoscopy data. Methods We performed a retrospective analysis of consecutive patients with A...
#1Nicolas Petitdidier (Paris 12 Val de Marne University)H-Index: 1
#2Laurent Beaugerie (UPMC: Pierre-and-Marie-Curie University)H-Index: 56
Last. Aurelien Amiot (Paris 12 Val de Marne University)H-Index: 9
view all 16 authors...
Summary Background Whether therapeutic drug monitoring (TDM) of infliximab should be implemented in daily practice is an ongoing controversy. Aims To assess the real-world use of TDM in an observational multicentre cohort study with consecutive patients with inflammatory bowel disease (IBD) treated with CT-P13. Methods Between September 2015 and December 2016, 364 patients with IBD were treated with CT-P13 in 13 gastroenterology departments and were followed up for 54 weeks. Disease activity, CT...
#1Moussa LaananiH-Index: 4
#1Moussa LaananiH-Index: 1
Last. Joël Coste (Paris V: Paris Descartes University)H-Index: 46
view all 6 authors...